Table 1.
Demographical and clinical data for each group.
| Control | FEP | SCZ | ASD | |
|---|---|---|---|---|
| N | 20 | 20 | 20 | 20 |
| Sex (M/F) | 13/7 | 10/10 | 14/6 | 15/5 |
| Age (years) | 31 ± 9 | 21 ± 2* | 32 ± 10 | 24 ± 5 |
| Years of education | 15 ± 3 | 12 ± 2 | 13 ± 3 | 14 ± 2 |
| Age of first episode | NA | 20 ± 2 | 21 ± 5 | 5 ± 3 |
| STROOP (s) | ||||
| Reading | 40 ± 9 | 48 ± 9 | 47 ± 8 | 47 ± 10 |
| Denomination | 55 ± 12 | 69 ± 14 | 71 ± 19* | 68 ± 15 |
| Interference | 87 ± 21 | 113 ± 32 | 120 ± 32* | 109 ± 30 |
| PANSS | ||||
| Positive symptoms | NA | 9 ± 2 | 10 ± 3 | NA |
| Negative symptoms | NA | 13 ± 6 | 15 ± 5 | NA |
| BPRS | NA | 36 ± 5 | 39 ± 6 | 38 ± 9 |
| Medication (mg/day) | NA | 182 ± 121 | 245 ± 267 | 258 ± 137 ∞ |
Demographical and clinical data (mean ± SD, except first two lines) for each of the four groups: Control subjects, patients with First-Episode Psychosis (FEP), with Schizophrenia (SCZ), and with Autism Spectrum Disorders (ASD). Years of education express school+higher education. Age of first psychotic episode, scores of clinical symptom scales, and medication (in mg of Chlorpromazine equivalent) were obtained for the relevant patient groups. All medicated patients received at least one atypical antipsychotic except one FEP and two SCZ patients. * denotes a significant difference from control (*=p < 0.05) (t-test). (∞) All FEP and SCZ patients and 4 ASD patients were treated with antipsychotics. The nine subjects added specifically for the decision tree analysis (6 women and 3 men) had a mean age of 31 ± 4.5 years.